Fluphenazine
- Generic Name
- Fluphenazine
- Brand Names
- Modecate
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26F3N3OS
- CAS Number
- 69-23-8
- Unique Ingredient Identifier
- S79426A41Z
- Background
A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.
- Indication
For management of manifestations of psychotic disorders.
- Associated Conditions
- Chorea, Depression, Gilles de la Tourette's Syndrome, Psychosis
- Associated Therapies
- Sedation
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Schizophrenia
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study site
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Pharmacovigilance in Gerontopsychiatric Patients
- Conditions
- DementiaDepressionSchizophreniaPsychosomatic DisordersAnxiety Disorders
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 407
- Registration Number
- NCT02374567
- Locations
- 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪Hannover Medical School, Hannover, Germany
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
- Conditions
- Schizophrenia and Disorders With Psychotic FeaturesSchizoaffective DisordersSchizophrenia
- Interventions
- Drug: Flupentixole
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 21
- Registration Number
- NCT02307396
- Locations
- 🇩🇪
Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
- Conditions
- Pathological Gambling
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 60
- Registration Number
- NCT02203786
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Fluphenazine Hydrochloride for Psoriasis
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00929578
- Locations
- 🇺🇸
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States
🇺🇸Robert Wood Johnson Medical School, Psoriasis Center of Excellence, New Brunswick, New Jersey, United States
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2009-01-13
- Lead Sponsor
- Immune Control
- Target Recruit Count
- 30
- Registration Number
- NCT00821301
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio, San Antonio, Texas, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Fluphenazine Decanoate for Psoriasis
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2010-12-22
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00356200
- Locations
- 🇺🇸
Tufts-New England Medical Center, Boston, Massachusetts, United States
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Immune Control
- Target Recruit Count
- 30
- Registration Number
- NCT00335647
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 150
- Registration Number
- NCT00161018
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
CATIE- Schizophrenia Trial
- Conditions
- Schizophrenia
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 1600
- Registration Number
- NCT00014001
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.